MedStar Health Research Institute, Hyattsville, Maryland, USA.
Am J Cardiol. 2011 Feb 1;107(3):399-405. doi: 10.1016/j.amjcard.2010.09.036.
Improved accuracy in predicting coronary heart disease (CHD) risk in patients with diabetes and kidney disease is needed. The addition of albuminuria to established methods of CHD risk calculation was reported in the Strong Heart Study (SHS) cohort. In this study, the addition of estimated glomerular filtration rate (eGFR) was evaluated using data from 4,549 American Indian SHS participants aged 45 to 74 years. After adjustment for Framingham CHD risk factors, hazard ratios for eGFR as a predictor of CHD were 1.69 (95% confidence interval 1.34 to 2.13) in women and 1.41 (95% confidence interval 0.94 to 2.13) in men. Models including albuminuria, eGFR, or both scored higher in discriminatory power than models using conventional risk factors alone in women; in men, the improvement was seen only for albuminuria and the combination of albuminuria and eGFR. Hosmer-Lemeshow assessments showed good calibration for the models using eGFR alone in both genders, followed by models including albuminuria alone in both genders. Adding eGFR improved the net reclassification improvement (NRI) in women (0.085, p = 0.0004) but not in men (0.010, p = 0.1967). NRI and integrated discrimination improvement (IDI) were improved in both genders using albuminuria and eGFR (NRI 0.135, p <0.0001, and IDI 0.027, p <0.0001 in women; NRI 0.035, p <0.0196, and IDI 0.008, p <0.0156 in men). Therefore, a risk calculator including albuminuria enhances CHD prediction compared to a calculator using only standard risk factors in men and women. Including eGFR alone improves risk prediction in women, but for men, it is preferable to include eGFR and albuminuria. In conclusion, this enhanced calculator should be useful in estimating CHD risk in populations with high prevalence of diabetes and renal disease.
需要提高预测糖尿病和肾病患者患冠心病 (CHD) 风险的准确性。在 Strong Heart 研究 (SHS) 队列中,已有研究报告将白蛋白尿添加到 CHD 风险计算的既定方法中。在这项研究中,使用来自 4549 名年龄在 45 至 74 岁的美国印第安 SHS 参与者的数据评估了估算肾小球滤过率 (eGFR) 的添加。在调整 Framingham CHD 风险因素后,eGFR 作为 CHD 预测因子的危险比为女性 1.69(95%置信区间 1.34 至 2.13),男性 1.41(95%置信区间 0.94 至 2.13)。在女性中,包含白蛋白尿、eGFR 或两者的模型在预测能力方面优于仅使用传统风险因素的模型;而在男性中,仅白蛋白尿和白蛋白尿与 eGFR 的组合可改善模型。Hosmer-Lemeshow 评估显示,在两性中仅使用 eGFR 的模型具有良好的校准,其次是在两性中仅使用白蛋白尿的模型。在女性中,添加 eGFR 可提高净重新分类改善 (NRI)(0.085,p = 0.0004),但在男性中则不然(0.010,p = 0.1967)。在两性中,使用白蛋白尿和 eGFR 可改善 NRI(女性 0.135,p<0.0001,IDI 0.027,p<0.0001;男性 0.035,p<0.0196,IDI 0.008,p<0.0156)。因此,与仅使用标准风险因素的计算器相比,包含白蛋白尿的风险计算器可提高男性和女性的 CHD 预测准确性。单独使用 eGFR 可改善女性的风险预测,但对于男性,最好同时包含 eGFR 和白蛋白尿。总之,这种增强的计算器应该有助于估计糖尿病和肾病患病率较高的人群中的 CHD 风险。